

PUBLISHED BY
THE MEDICAL RESEARCH SOCIETY AND THE BIOCHEMICAL SOCIETY

Printed in Great Britain by Spottiswoode Ballantyne Ltd.
Colchester and London

Volume 59

AUTHOR INDEX

- ALBERTI, K.G.M.M. 155-161, 191-198
 AMIS, T.C. 485-492
 ANTHONISEN, N.R. 115-121
 ARNER, P. 199-201
 BÄCKER, A. 67-70
 BACON, S. 509-511
 BALASUBRAMANIAN, V. 497-500
 BARRAGRY, J.M. 293-296
 BARTTER, F.C. 397-400
 BARTON, M. 479-483
 BARTON, R.N. 19-27
 BEER, M.S. 293-296
 BELLINGHAM, A.J. 163-168
 BEST, L.C. 131-135
 BIRGEGÅRD, G. 385-387
 BLACKBURN, A.M. 237-243
 BLOOM, S.R. 1-6, 237-243, 457-462, 505-508
 BLUME, R. 373-380
 BOUCHER, B.J. 293-296
 BRADA, M. 163-168
 BRYANT, M.G. 1-6, 457-462, 505-508
 BURSTON, D. 285-287
 CALDWELL, P.R.B. 337-345
 CAMNER, P. 79-84
 CAMPBELL, E.J.M. 493-495
 CARTER, A. 509-511
 CASHMAN, P.M.M. 497-500
 CASPARY, W.F. 373-380
 CERULLI, N. 143-145
 CHAN, W. 443-449
 CHANARIN, I. 151-154
 CHASE, R.A. 191-198
 CHOW, F.P.R. 369-372
 CHRISTENSEN, N.J. 251-256
 CHRISTOFIDES, N.D. 237-243, 505-508
 CIOFETTA, G. 485-492
 CLARK, W.F. 147-150
 CLARKE, H. 115-121
 CLEMENS, T.L. 257-263
 COHEN, R.D. 293-296
 COLTART, D.J. 207-209
 COOPER, M.J. 123-129
 COX, A.G. 505-508
 CRILLY, R.G. 137-142
 DANDONA, P. 369-372
 DAVIES, P. 191-198
 DAWSON, J. 1-6, 457-462, 505-508
 DEHENEFJE, J. 435-441
 DE JONG, P.E. 245-250
 DE JONG-VAN DEN BERG, L.T.W. 245-250
 DENNIS, S.C. 207-209
 DE WARDENER, H.E. 411-421
 DHINGRA, S. 115-121
 DONKER, A.J.M. 245-250
 DOWLING, R.H. 317-327, 329-336
 DRIEDGER, A.A. 147-150
 DUBOWITZ, V. 7-12
 DUFFY, B.J. 13-18
 DURRINGTON, P.N. 71-74
 DÜSING, R. 67-70, 75-77
 EBEID, F.H. 237-243
 EBRINGER, R.W. 405-410
 EDEN, J. 67-70
 EDMONDS, C.J. 29-39
 EDWARDS, R.H.T. 463-468
 ELIA, M. 275-283, 509-511
 ELSASSER, U. 393-395
 ELSENHANS, B. 373-380
 EPSTEIN, M. 55-62
 ERIKSSON, S. 173-181
 ESPINER, E.A. 443-449
 FARRELL, R. 275-283
 FLORAS, J.S. 347-352
 FORSLING, M.L. 501-503
 FRAHER, L.J. 257-263
 FRANKEL, H.L. 251-256
 FRAYN, K.N. 19-27
 FYHRQUIST, F. 381-383
 GALLERY, E.D.M. 49-53
 GHATEL, M.A. 237-243
 GIULIANI, A. 143-145
 GLÄNZER, K. 67-70, 75-77
 GORDON, D. 231-236
 GRIFFITHS, J.R. 225-230
 GROSS, E. 211-214
 GÜLLNER, H.-G. 397-400
 GYÖRY, A.Z. 49-53
 HABER, E. 55-62
 HEARSE, D.J. 207-209
 HEATH, D.F. 19-27
 HEGENFELDT, L. 173-181
 HEIGENHAUSER, G.J.F. 469-478
 HEINRICH, R. 75-77
 HESP, R. 393-395
 HILTON, P.J. 353-357
 HOLBROOK, I.B. 211-214
 HOLGATE, S.T. 155-161
 HORSMAN, A. 137-142
 HOULT, J.R.S. 63-66
 HUGHES, C.A. 317-327, 329-336
 HUGHES, J.M.B. 485-492
 HUTTON, R.A. 369-372
 ILES, R.A. 225-230
 ILIC, V. 275-283
 IKRAM, H. 443-449
 IRVING, M.H. 211-214
 JAMES, O. 479-483
 JENKINS, W. 7-12
 JOHNSON, V.E. 353-357
 JONES, J.V. 347-352
 JONES, N.L. 85-91, 469-478
 JONES, P.B.B. 131-135
 JONES, R.B. 353-357
 KAFKA, M.S. 397-400
 KARPATI, L. 369-372
 KELMAN, A.W. 311-315
 KERMODE, J.C. 29-39
 KEYES, S.J. 93-103
 KILLIAN, K.J. 493-495
 KIPNOWSKI, J. 67-70, 75-77
 KLENERMAN, L. 393-395
 KNOCK, C.A. 411-421, 423-433
 KRAMER, H.J. 67-70, 75-77
 KRÜCK, F. 67-70
 KUKSIS, A. 469-478
 LANIER, B.R. 289-292
 LEATHERDALE, B.A. 191-198
 LEBOWITZ, J. 289-292
 LEE, G. DE J. 105-113
 LEIJD, B. 203-206

- LEVICK, J.R. 41–48
 LEWIS, B. 359–367
 LIFSCHITZ, M.D. 55–62
 LIGHTMAN, S.L. 501–503
 LINDSAY, R.M. 147–150
 LINTON, A.L. 147–150
 LITTLE, R.A. 19–27
 LOH, L. 485–492
 LONG, R.G. 293–296
 LUND, T. 297–299

 MCANULTY, R. 93–103
 MCCAUGHEY, E.S. 155–161
 MACKLON, A.F. 479–483
 MAFFI, D. 143–145
 MAGILL, P.J. 359–367
 MAHUTTE, C.K. 493–495
 MANN, S. 497–500
 MANNING, A.S. 207–209
 MARSHALL, D.H. 137–142
 MATHIAS, C.J. 251–256
 MATSOS, C.G. 469–478
 MATTHEWS, D.M. 285–287
 MELICK, R.A. 401–404
 MICHAEL, J. 353–357
 MILOJEVIC, S. 183–189
 MILEWSKI, P.J. 211–214
 MILLAR CRAIG, M.W. 497–500
 MILLER, N.E. 359–367
 MIRKIN, B.L. 123–129
 MITCHELL-HEGGS, P. 93–103
 MITCHENERE, P. 293–296
 MOORE, P.K. 63–66
 MORGAN, B. 93–103
 MORRIS, C.J. 265–273
 MORROW, G. 289–292
 MORTON, J.J. 451–456
 MOTIL, K.J. 13–18
 MOXHAM, J. 463–468
 MURDOCH, R.D. 389–391

 NEWHAM, D. 463–468
 NICHOLLS, M.G. 443–449
 NIZET, A. 435–441
 NORDIN, B.E.C. 137–142

 O'RIORDAN, J.L.H. 257–263
 ÖSTMAN, J. 199–201

 PAPAPOULOS, S.E. 257–263
 PARSONS, H.G. 13–18
 PATRICK, J. 353–357
 PEART, W.S. 251–256, 337–345
 PENCHARZ, P.B. 13–18
 PETERS, T.J. 1–6, 7–12, 457–462, 505–508
 POULSEN, K. 297–299
 PRICHARD, J.S. 105–113
 PRINCE, A. 329–336
 PRIOR, W. 67–70
 PUUTULA-RÄSÄNEN, L. 381–383

 QUELCH, K.J. 401–404

 RAFTERY, E.B. 497–500
 RAJAGOPALAN, B. 105–113
 RALPHS, D.N.L. 237–243
 RAMPTON, D.S. 389–391
 RAO, S.N. 359–367
 RAWBONE, R.G. 93–103
 RAWLINS, M.D. 479–483
 RE, R. 55–62
 RECORD, C.O. 191–198
 REDEL, J. 257–263
 REEVE, J. 169–172
 REID, B.D. 147–150
 RHODES, M. 401–404
 RIGBY, R.J. 147–150
 ROBIN, M. 435–441
 ROBINSON, L.A. 163–168
 RODDIS, S.A. 231–236
 ROGERS, J. 191–198
 ROWE, J. 49–53
 ROYSTON, J.P. 169–172
 RUSSELL, R.G.G. 131–135

 SAGNELLA, G.A. 337–345
 SARSON, D.L. 237–243
 SCHOUTEN, H. 245–250
 SEVER, P.S. 231–236

 SEVERINI, G. 143–145
 SEWRAJSINGH, G.S. 245–250
 SHIPLEY, K. 211–214
 SIMPSON, M. 137–142
 SINAIKO, A.R. 123–129
 SLADEN, G.E. 389–391
 SMITH, R. 215–223, 275–283, 509–511
 SNASHALL, P.D. 93–103
 SONNENBERG, H. 183–189
 STATIUS VAN EPS, L.W. 245–250
 STELKENS, H. 75–77
 STEPHENS, W.P. 71–74
 STINNESBECK, B. 67–70
 STOKES, G.S. 49–53
 STONER, H.B. 19–27
 STUBBS, W.A. 155–161
 SÜFKE, U. 373–380
 SUTTON, J.R. 469–478

 TATTERSFIELD, A.E. 155–161
 TAYLOR, E. 285–287
 TELLEZ, M. 169–172
 THRELFALL, C.J. 19–27
 TIKKANEN, I. 381–383
 TOEWS, C.J. 469–478
 TREE, M. 451–456

 VALENTE, A.J. 265–273
 VEALL, N. 169–172
 VERESS, A.T. 183–189
 VUUST, J. 297–299

 WAHREN, J. 173–181
 WALTON, K.W. 265–273
 WHITING, B. 311–315
 WILES, C.M. 463–468
 WILLIAMS, J. 49–53
 WILLIAMSON, D.H. 275–283
 WOOD, P.J. 155–161
 WOOLLARD, M.L. 369–372
 WOOTTON, R. 169–172, 393–395

 YATES, D.W. 19–27

Volume 59

SUBJECT INDEX

First and last page numbers of papers to which entries refer are given.
Page numbers marked with an asterisk refer to Editorial Reviews.

- Absorption**
 amino acids 285–287, 373–380
 carbohydrate gelling agents 373–380
 dipeptide 285–287
 galactose 317–327
 monosaccharide 373–380
- Accidental hypothermia** 19–27
- Acetoacetate oxidation, perfused heart** 289–292
- Acidosis, heavy exercise** 85–91*
- Adenosine 3':5'-phosphate, adipose tissue lipolysis** 199–201
- Adipose tissue, cyclic AMP** 199–201
- Adolescence, nitrogen metabolism** 13–18
- Adrenergic resistance, salbutamol** 155–166
- α -Adrenoreceptors**
 indomethacin 397–400
 indoramin 497–500
- β -Adrenoreceptor blockade**
 chronic 207–209
 indomethacin 397–400
- Age, diazepam pharmacokinetics** 479–483
- Aged patients, hypothermia** 19–27
- Airway resistance, salbutamol** 155–161
- Airways, tracheobronchial tree** 79–84*
- Albumin, transvascular flux in oedema** 105–113
- Alloxan, transvascular albumin flux** 105–113
- Aldosterone**
 chronic frusemide therapy 443–449
 renin and prostaglandin E 55–62
- Ambulatory monitoring** 497–500
- Amino acids**
 absorption 285–287
 branched-chain 173–181, 275–283
 hypothermia 19–27
 infused leucine 173–181
- Amino [^{15}N]nitrogen** 13–18
- Angiotensin**
 hypotensive effect of captopril 451–456
 renin–angiotensin–aldosterone axis 55–62
- Angiotensin I-converting enzyme** 451–456
- Angiotensin II, captopril** 451–456
- Ankylosing spondylitis, HLA-B27** 405–410*
- Aorta, thoracic, prostacyclin-like activity** 369–372
- Apoproteins (A I and A II), metabolism** 359–367
- Arrhythmia, quantification** 207–209
- Arteriovenous differences, hypothermia** 19–27
- Asthma, salbutamol** 155–161
- Bacteriology, intestinal, parenteral feeding** 329–336
- Baroreflex, experimental hypertension** 347–352
- Bicarbonate, heavy exercise** 85–91*
- Bile acid, obesity** 203–206
- Blood platelets**
 ^{111}In -labelled in glomerulonephritis 147–150
 thromboxane and malondialdehyde 131–135
- Blood pressure**
 ambulant 497–500
 captopril 451–456
 volume expansion 411–421, 423–433
- Blood volume, expansion** 411–421, 423–433
- Bone, trabecular and cortical** 393–395
- Bone loss, calcium balance in women** 137–142
- Brain, uptake of leucine** 173–181
- Bronchial narrowing, pulmonary oedema** 93–103
- Bronchofibrescope** 79–84*
- Calcium (^{47}Ca) absorption, intestinal** 169–172
- Calcium balance, bone loss** 137–142
- Calcium metabolism, bone disorders** 215–223*
- Captopril (SQ 14 225), hypotensive effect** 451–456
- Carbohydrate gelling agent** 373–380
- Catecholamines, tetraplegia** 251–256
- Chenodeoxycholic acid, obesity** 203–206
- Cholesterol, insulin in diabetes** 71–74
- Cholic acid, obesity** 203–206
- Cirrhosis, forearm glucose uptake** 191–198
- Cobalamins, nitrous oxide** 151–154*
- Coitus, propranolol effects** 231–236
- Collagen** 215–223*
- Colon**
 mucosal peptide hormones 457–462
 transepithelial potassium 29–39
- Computed tomography** 393–395
- Concanavalin A, binding** 385–387
- Core temperature, hypothermia** 19–27

- Cortisol, hypothermia 19–27
 Creatinine excretion, myofibrillar protein
 breakdown 211–214
 Cryoactivation, plasma renin 49–53
 Cyclic AMP *see* Adenosine 3':5'-phosphate
 Cytosol
 properties in Pompe's disease 1–6
 rectal mucosal biopsies 457–462

 Deconvolution measurements 169–172
 Diabetes
 prostaglandin metabolism 63–66
 serum high-density lipoprotein cholesterol
 71–74
 Diaphragm, bilateral paralysis 485–492
 Diazepam, age on pharmacokinetics 479–483
 Diet, vegetarian 509–511
 Dietary fibre 373–380
 25,26-Dihydroxycholecalciferol 257–263
 2,3-Diphosphoglycerate
 dialysis in uraemia 143–145
 intra-erythrocytic by ³¹P n.m.r. 225–230*
 Diuretic, frusemide 443–449
 Diuretics, prostaglandin interaction 67–70
 Diurnal variation, immunoreactive substance P
 75–77
 Dose–response, hypotension and captopril
 451–456
 Dumping syndrome, neurotensin 237–243
 Dyspnoea, respiratory load detection 493–495

 Encephalopathy, portal-systemic 173–181
 Endoplasmic reticulum
 density gradient localization 7–12
 Pompe's disease 7–12
 rectal mucosal biopsies 457–462
 Enkephalin, vasopressin 501–503
 Enterocutaneous fistula, urinary nitrogen 211–
 214
 Enteroglucagon, dumping syndrome 237–243
 Enzyme
 inhibitors for renin assay 381–383
 organelle markers 1–6
 rectal mucosa 457–462
 Erythrocyte
 methylprednisolone 163–168
 n.m.r. proton spectra 225–230*
 Ethinyloestradiol, prostacyclins 369–372
N-Ethylmaleimide, proteolytic inhibitor 337–
 345
 Exercise, metabolic acidosis 85–91*

 Fatty acids, metabolism during exercise 463–
 468
 Femur fracture
 bone loss, calcium balance 137–142
 trabecular and cortical bone 393–395

 Ferritin
 glucosylation 385–387
 source during infection 385–387
 synthesis 385–387
 Gases, radioactive, lung distribution 485–492
 Gastric inhibitory polypeptide 237–243
 Gastrointestinal hormones
 gastric antrum 1–6
 rectal mucosa 457–462
 serotonin and motilin 505–508
 Glomerulonephritis, chronic 147–150
 Glucose
 forearm arteriovenous difference in cirrhosis
 191–198
 hypothermia 19–27
 metabolism during exercise 463–468
 Glycerol
 hypothermia 19–27
 lipolysis index 463–468
 Glycogen-storage disease, type II 7–12
 Glycyl-L-leucine, transport kinetics 301–309

 Haemodialysis, blood oxygen transport 143–
 145
 Haemodynamics, cardiac failure 443–449
 Haemoglobin, methylprednisolone 163–168
 Heart
 failure, myocardial infarction 115–121
 frusemide 443–449
 ischaemia, ³¹P n.m.r. studies 225–230*
 propranolol-withdrawal syndrome 207–209
 Hepatocytes, ³¹P n.m.r. spectra 225–230*
 High-density lipoproteins
 insulin in diabetes 71–74
 primary hypertriglyceridaemia 359–367
 High-molecular-weight renin 337–345
 Histamine, ulcerative colitis 389–391
 HLA histocompatibility antigen 405–410*
 Hydrogen ion, production in acidosis 85–91*
 25-Hydroxycholecalciferol 257–263
 6-Hydroxydopamine, sympathectomy in spon-
 taneous hypertension 123–129
 Hydroxylysine, collagen metabolism 215–223*
 Hydroxyproline, collagen metabolism 215–
 223*
 25-Hydroxy-vitamin D, hyperbilirubinaemia
 293–296
 Hyperparathyroidism bone loss, calcium balance
 137–142
 Hypertension
 neonatal sympathectomy 123–129
 pre-eclampsia 49–53
 renal, Goldblatt two-kidney one-clip 347–
 352
 Hypertriglyceridaemia, apoprotein metabolism
 359–367
 Hypotension, haemorrhagic 105–113

- Hypothermia 19–27
- Hypoplasia, intestinal mucosal 317–327
- Immunoreactive substance P 75–77
- Indium (^{111}In)-labelled platelets, glomerulonephritis 147–150
- Indomethacin
adrenoreceptors 397–400
renal prostaglandin system 67–70
sickle cell anaemia 245–250
- Indoramin, α -adrenoreceptor antagonist 497–500
- Infection, serum ferritin 385–387
- Inferior vena cava, prostacylin-like activity 369–372
- Injury, infused leucine removal 275–283
- Insulin
hypothermia 19–27
resistance 191–198
- Intestine
adaptation to parenteral feeding 317–327, 329–336
monosaccharide, amino acid transport 373–380
- Intra-articular hydrostatic pressure 41–48
- Jaundice, hyperbilirubinaemia 293–296
- Jejunum
dipeptide absorption 285–287
serotonin and motilin 505–508
- Joint, synovial, artificial effusion 41–48
- Kaliuresis, spironolactone on renal prostaglandins 67–70
- Ketone bodies
hypothermia 19–27
propionate metabolism 289–292
- Ketosis, propionate in disease 289–292
- Kidney
hypervolaemia 183–189
ischaemia, ^{31}P n.m.r. studies 225–230*
prostaglandins in diabetes mellitus 63–66
regulation of sodium 435–441
renin precursor 297–299
sialic acid 401–404
transplant 435–441
- Kidney function test 245–250
- Klebsiella pneumoniae*, ankylosing spondylitis 405–410*
- Krypton ($^{81\text{m}}\text{Kr}$, $^{85\text{m}}\text{Kr}$), regional lung function 485–492
- Lactate
cirrhosis 191–198
fat metabolism 463–468
heavy exercise 85–91*, 463–468
hypothermia 19–27
- Leucine, infusion 173–181, 275–283
- Leucocytes, zinc transport 353–357
- Lipolysis, cyclic AMP 199–201
- Lipoproteins, high-density
insulin in diabetes 71–74
primary hypertriglyceridaemia 359–367
- Lipoproteins, low-density, receptors 265–273
- Lithium, transepithelial 29–39
- Liver, ^{31}P -n.m.r. spectra of hepatocytes 225–230*
- Liver disease
cirrhosis 191–198
Pompe's disease 7–12
- Loaded breathing, passive ventilation 493–495
- Low-density lipoprotein receptors 265–273
- Low-molecular-weight renin 337–345
- Lung
mechanics 485–492
open-chested ventilation 105–113
prostaglandin in diabetes mellitus 63–66
- Lymphoblastoid cells, rosette-forming technique 265–273
- Lysosomes
density gradient localization 7–12
Pompe's disease 7–12
rectal mucosa 457–462
- Malondialdehyde, thromboxane and blood platelets 131–135
- Mathematical analysis of clinical diagnosis 301–309
- Menopause bone loss, calcium balance 137–142
- Messenger RNA, renin precursor 297–299
- Methionine
enkephalin analogue (DAMME) 501–503
nitrous oxide 151–154*
- N^{α} -Methylhistidine excretion
myofibrillar protein breakdown 211–214
vegetarian diet 509–511
- Methylprednisolone, erythrocytes and haemoglobin 163–168
- Mitochondria
density gradient localization 7–12
Pompe's disease 7–12
rectal mucosa 457–462
- Monosaccharide absorption, carbohydrate gelling agent 373–380
- Morphometry, bone loss and calcium balance 137–142
- Motilin
dumping syndrome 237–243
jejunum localization 505–508
- Mucociliary function, chronic diseases 79–84*
- Mucosa, gastrointestinal
gastric 1–6
hypoplasia, hypofunction 317–327
rectal 457–462

- Muscle, skeletal
 leucine uptake 173–181
 3-methylhistidine excretion 509–511
 protein breakdown 211–214
 pH during heavy exercise 85–91*
 superfused, n.m.r. studies 225–230*
- Myocardial infarction, ventilatory pattern and drive 115–121
- Natriuretic factor 183–189
- Nephrectomy, dihydroxy metabolite 257–263
- Natriuresis
 blood-volume expansion 411–421, 423–433
 frusemide on renal prostaglandins 67–70
- Neurotensin, dumping syndrome 237–243
- Nitrous oxide, cobalamins 151–154*
- Non-esterified fatty acids, hypothermia 19–27
- Noradrenaline, propranolol during coitus 231–236
- Norethisterone, prostacyclins 369–372
- Nuclear magnetic resonance, metabolism 225–230*
- Obesity
 cholesterol and bile acid metabolism 203–206
 nitrogen metabolism 13–18
- Occlusion pressure 115–121
- Osteogenesis imperfecta, type I collagen disorder 215–223*
- Osteoporosis, bone loss, calcium balance 137–142
- Oxygen affinity
 methylprednisolone 163–168
 uraemia 143–145
- Pancreas, parenteral nutrition 329–336
- Parenteral feeding, exclusive 329–336
- Peroxisomes
 density gradient localization 1–6
 rectal mucosa 457–462
- Pharmacodynamics, modelling drug response 311–315
- Pharmacokinetics, diazepam 479–483
- Pharmacokinetic parameters 311–315*
- Plasma membrane
 density gradient localization 7–12
 Pompe's disease 7–12
 rectal mucosa 457–462
- Platelets, blood
 ¹¹¹In-labelled in glomerulonephritis 147–150
 malondialdehyde and thromboxane 131–135
- Pompe's disease 7–12
- Posture
 effect on immunoreactive substance P 75–77
 head-up tilt in paraplegia 251–256
- Potassium, transepithelial 29–39
- Pregnancy, hypertension and plasma renin 49–53
- Propionate, metabolism in ketosis 289–292
- Protein metabolism, obese adolescents 13–18
- Propranolol
 effects during coitus 231–236
 withdrawal syndrome 207–209
- Prostacyclin activity 369–372
- Prostaglandin
 indomethacin 397–400
 metabolizing enzymes, diabetes 63–66
 renal 55–62, 67–70
- Prostaglandin synthase 63–66
- Pseudomonas pyocyanea*, increased transvascular albumin flux 105–113
- Pulmonary oedema
 airways 93–103
 transvascular albumin flux 105–113
- Radioactive gases, lung distribution 485–492
- Radioimmunoassay circulating 25,26-dihydroxycholecalciferol 257–263
- Radioisotope kinetics, transepithelial ⁴³K 29–39
- Rectum, histamine release 389–391
- Regional lung volume, pulmonary oedema 93–103
- Renal prostaglandins
 interaction of diuretics 67–70
 renin–angiotensin–aldosterone relationship 55–62
- Renin
 enzyme inhibitors 381–383
 head-up tilt 251–256
 precursors identified by mRNA 297–299
 pregnancy 49–53
 protein inhibitor 337–345
 storage form 337–345
- Renin–angiotensin system
 aldosterone and prostaglandins 55–62
 congestive heart failure 443–449
 neonatal sympathectomy 123–129
 sodium excretion 435–441
 spontaneous hypertension 123–129
- Respiratory exchange ratio, exercise 463–468
- Respiratory muscle fatigue 463–468
- Respiratory sensation 493–495
- Rheumatic diseases, HLA histocompatibility antigen 405–410*
- Salbutamol, airway and metabolic resistance 155–161
- Serotonin, jejunum localization 505–508
- Sialic acid, kidney stone matrix 401–404
- Sickle cell anaemia, renal haemodynamics 245–250
- Skeletal muscle *see* Muscle, skeletal

- Sodium
 balance, immunoreactive substance P 75-77
 excretion 411-421, 423-433
 intrarenal regulation 435-441
 transepithelial, colon 29-39
- Spontaneous hypertension, neonatal sympathectomy 123-129
- Starvation, leucine removal 275-283
- Steroid balance, obesity 203-206
- Stomach, mucosal peptide hormones 1-6
- Sternomastoid muscle function 463-468
- Streptozotocin, induced diabetes 71-74
- Strontium (⁸⁵Sr), deconvolution measurements 169-172
- Subcellular fractionation
 gastric antral biopsies 1-6
 jejunum 505-508
 Pompe's disease 7-12
 rectal mucosa 457-462
 serotonin and motilin 505-508
- Sympathectomy, neonatal 123-129
- Sympathetic nervous system, tetraplegia 251-256
- Synovial fluid, artificial effusion absorption 41-48
- Tetraplegia, sympathetic nervous system 251-256
- Thoracic aorta, prostaglandin-like activity 369-372
- Thrombocytes *see* Platelets
- Thromboxane B₂, blood platelets and malondialdehyde 131-135
- Tilt, vasopressin response 501-503
- Total parenteral nutrition, intestinal adaptations 317-327
- Tracheobronchial tree, clearance of particles 79-84*
- Transplant, kidney 435-441
- Transport
 affinity systems 301-309
- Transport (*continued*)
 blood oxygen 143-145
 intestinal 285-287
 kinetics 301-309, 373-380
 zinc 353-357
- Triglycerides, insulin in diabetes 71-74
- Tumour cells, pH difference by ³¹P n.m.r. 225-230*
- Ulcerative colitis, histamine 389-391
- Ultrafiltration, blood oxygen transport 143-145
- Ultraviolet radiation, 25-hydroxy-vitamin D 293-296
- Uraemia, dialysis and ultrafiltration 143-145
- Urea, sickle cell anaemia 245-250
- Vasopressin, response to tilt 501-503
- Vena cava, inferior, prostacyclin-like activity 369-372
- Ventilation
 heavy exercise 85-91*
 passive 493-495
 perfusion relationship 93-105
 myocardial infarction 115-121
 sternomastoid fatigue 463-468
- Ventilatory drive 115-121
- Vitamin B₁₂, nitrous oxide 151-154*
- Vitamin D deficiency,
 dihydroxy metabolite 257-263
- Volume regulation 183-189
- Water
 absorption, indomethacin and diuretics 67-70
 immersion 55-62
 interstitial volume 105-113
- Water immersion
 renin-aldosterone and prostaglandin dissociation 55-62
- Zinc, transport in leucocytes 353-357